{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:08Z","timestamp":1790089628090,"version":"4.0.1"},"reference-count":15,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>An increase in the absolute lymphocyte count (ALC) is a component of progressive disease (PD) in chronic lymphocytic leukemia (CLL) and contributes to progression-free survival in phase 3 trials. Prior studies with chemoimmunotherapy demonstrated that PD by ALC alone (ALC PD) conferred better outcomes than other modalities of PD (other PD). To evaluate the incidence and impact of ALC PD with modern treatments, we retrospectively examined 339 consecutive patients with CLL\/small lymphocytic lymphoma treated between 2016 and 2025 at the University of Washington\/Fred Hutchinson Cancer Center. Patients received frontline therapy with continuous Bruton tyrosine kinase inhibitors (BTKi; n = 179), bendamustine-rituximab (BR; n = 66), and time-limited B-cell lymphoma 2 inhibitors (BCL2i; n = 94). The cumulative incidence of ALC PD was higher with BR than BTKi and BCL2i (P = .021). Across treatment groups, overall survival (OS) from progression was longer for ALC PD than other PD (median, 116 vs 71 months; P = .0012; hazard ratio [HR], 3.15; 95% confidence interval [CI], 1.52-6.53), with 5-year OS rates of 83% and 56%, respectively. Time to next treatment or death (TTNT-D) was longer for ALC PD (median, 14 vs 2.2 months; P&amp;lt; .0001). OS from treatment initiation was longest for nonprogressors, intermediate for ALC PD (HR, 3.62; 95% CI, 1.48-8.85), and worst for other PD (HR, 11.7; 95% CI, 5.99-22.9). These findings suggest that ALC PD may vary based on treatment modality and is associated with longer survival and TTNT-D. If confirmed in larger phase 3 data sets, future response criteria may consider reporting ALC PD separately from other PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020680","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:56:04Z","timestamp":1784296564000},"page":"6291-6298","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and clinical impact of absolute lymphocyte count\u2013only progression in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5830-1475","authenticated-orcid":false,"given":"Xiancheng","family":"Wu","sequence":"first","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-4404","authenticated-orcid":false,"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-1588","authenticated-orcid":false,"given":"Timothy W.","family":"Randolph","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-1510","authenticated-orcid":false,"given":"Chaitra S.","family":"Ujjani","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Crider","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8392-6956","authenticated-orcid":false,"given":"Sara","family":"Keshmiri","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Martin","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"1Clinican Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"25","key":"2026092210530137400_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2026092210530137400_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"7","key":"2026092210530137400_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026092210530137400_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.25561","article-title":"Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)","volume":"94","author":"Al-Sawaf","year":"2019","journal-title":"Am J Hematol"},{"issue":"16","key":"2026092210530137400_bib5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026092210530137400_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"2026092210530137400_bib7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"2026092210530137400_bib8","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/bloodadvances.2017011262","article-title":"Early progression of disease as a predictor of survival in chronic lymphocytic leukemia","volume":"1","author":"Ahn","year":"2017","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026092210530137400_bib9","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1182\/blood-2025-5667","article-title":"Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)","volume":"146","author":"Hampel","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026092210530137400_bib10","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/blood-2025-2107","article-title":"Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: a pooled analysis of fixed-duration therapies","volume":"146","author":"Simon","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026092210530137400_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.23.02410","article-title":"Delaying prostate-specific antigen progression in biochemically recurrent prostate cancer: is it clinically meaningful?","volume":"42","author":"Childs","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026092210530137400_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","article-title":"Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed","volume":"20","author":"Walia","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2026092210530137400_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026092210530137400_bib14","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2022007082","article-title":"Outcomes after biochemical or clinical progression in patients with multiple myeloma","volume":"7","author":"Goldman-Mazur","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026092210530137400_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6291\/2589189\/blooda_adv-2026-020680-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6291\/2589189\/blooda_adv-2026-020680-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:53:08Z","timestamp":1790088788000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6291\/569755\/Incidence-and-clinical-impact-of-absolute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":15,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020680","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,14]]}}}